Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 173

Similar articles for PubMed (Select 21121840)

1.

Inhibition of mutated BRAF in melanoma.

Kim T, Kim J, Lee MG.

N Engl J Med. 2010 Dec 2;363(23):2261; author reply 2261-2. doi: 10.1056/NEJMc1010755#SA1. No abstract available.

PMID:
21121840
2.

Inhibition of mutated, activated BRAF in metastatic melanoma.

Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB.

N Engl J Med. 2010 Aug 26;363(9):809-19. doi: 10.1056/NEJMoa1002011.

3.

Resistance to BRAF inhibition in melanomas.

Solit DB, Rosen N.

N Engl J Med. 2011 Feb 24;364(8):772-4. doi: 10.1056/NEJMcibr1013704. No abstract available.

PMID:
21345109
4.

Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma.

Koop A, Satzger I, Alter M, Kapp A, Hauschild A, Gutzmer R.

Br J Dermatol. 2014 Jan;170(1):220-2. doi: 10.1111/bjd.12615. No abstract available.

PMID:
24032672
5.

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, Lieftink C, Mateus C, Vagner S, Grernrum W, Hofland I, Schlicker A, Wessels LF, Beijersbergen RL, Bardelli A, Di Nicolantonio F, Eggermont AM, Bernards R.

Nature. 2014 Apr 3;508(7494):118-22. doi: 10.1038/nature13121. Epub 2014 Mar 26.

PMID:
24670642
6.

Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.

Goldinger SM, Zimmer L, Schulz C, Ugurel S, Hoeller C, Kaehler KC, Schadendorf D, Hassel JC, Becker J, Hauschild A, Dummer R; Dermatology Cooperative Oncology Group (DeCOG).

Eur J Cancer. 2014 Jan;50(2):406-10. doi: 10.1016/j.ejca.2013.09.014. Epub 2013 Oct 29.

PMID:
24183461
7.

When are signal transduction targeted therapies acting as immunotherapy?

Flaherty KT.

Cancer Biol Ther. 2015;16(5):645-7. doi: 10.1080/15384047.2015.1030553. No abstract available.

PMID:
25807058
8.

Getting around PLX4032: studies turn up unusual mechanisms of resistance to melanoma drug.

Tuma RS.

J Natl Cancer Inst. 2011 Feb 2;103(3):170-1, 177. doi: 10.1093/jnci/djr016. Epub 2011 Jan 17. No abstract available.

9.

[Treatment of metastatic melanoma with BRAF inhibitors].

Hafner C.

Hautarzt. 2011 Sep;62(9):696-8. doi: 10.1007/s00105-011-2232-8. German. No abstract available.

PMID:
21863388
10.

Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.

Sharma A, Shah SR, Illum H, Dowell J.

Drugs. 2012 Dec 3;72(17):2207-22. doi: 10.2165/11640870-000000000-00000. Review.

PMID:
23116250
11.

Vemurafenib.

Flaherty KT, Yasothan U, Kirkpatrick P.

Nat Rev Drug Discov. 2011 Oct 31;10(11):811-2. doi: 10.1038/nrd3579.

PMID:
22037033
12.

Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.

Bahadoran P, Allegra M, Le Duff F, Long-Mira E, Hofman P, Giacchero D, Passeron T, Lacour JP, Ballotti R.

J Clin Oncol. 2013 Jul 1;31(19):e324-6. doi: 10.1200/JCO.2012.46.1061. Epub 2013 May 28. No abstract available.

13.

Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.

Su F, Bradley WD, Wang Q, Yang H, Xu L, Higgins B, Kolinsky K, Packman K, Kim MJ, Trunzer K, Lee RJ, Schostack K, Carter J, Albert T, Germer S, Rosinski J, Martin M, Simcox ME, Lestini B, Heimbrook D, Bollag G.

Cancer Res. 2012 Feb 15;72(4):969-78. doi: 10.1158/0008-5472.CAN-11-1875. Epub 2011 Dec 28.

14.

Effectively targeting BRAF in melanoma: a formidable challenge.

Fecher LA, Amaravadi R, Schuchter LM.

Pigment Cell Melanoma Res. 2008 Aug;21(4):410-1. doi: 10.1111/j.1755-148X.2008.00485.x. No abstract available.

PMID:
18710372
15.

NICE guidance on vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma.

Perampaladas K, Hay N, Rinaldi F, Robertson J, Adam J.

Lancet Oncol. 2013 Jan;14(1):20-1. No abstract available.

PMID:
23401870
16.

PLX4032 and melanoma: resistance, expectations and uncertainty.

Roukos DH.

Expert Rev Anticancer Ther. 2011 Mar;11(3):325-8. doi: 10.1586/era.11.3. No abstract available.

PMID:
21417847
17.

Community experience of vemurafenib for BRAF(V600) melanoma.

Hersey P.

Lancet Oncol. 2014 Apr;15(4):369-70. doi: 10.1016/S1470-2045(14)70079-8. Epub 2014 Feb 27. No abstract available.

PMID:
24582506
18.

The natural history of malignancies under conditions of BRAF inhibitor stimulation.

White RM.

Expert Opin Investig Drugs. 2011 Jan;20(1):135-6. doi: 10.1517/13543784.2011.542325. Epub 2010 Nov 30. No abstract available.

PMID:
21117980
19.

Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.

Tap WD, Gong KW, Dering J, Tseng Y, Ginther C, Pauletti G, Glaspy JA, Essner R, Bollag G, Hirth P, Zhang C, Slamon DJ.

Neoplasia. 2010 Aug;12(8):637-49.

20.

Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.

Luke JJ, Hodi FS.

Oncologist. 2013 Jun;18(6):717-25. doi: 10.1634/theoncologist.2012-0391. Epub 2013 May 24. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk